Moderna
MRNA
$50.73
-4.01%
Moderna, Inc. is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, operating within the dynamic and high-risk biotech industry. The company established itself as a leading platform technology innovator, validated by the rapid global deployment of its COVID-19 vaccine, and now seeks to leverage its mRNA platform across a broad pipeline spanning infectious diseases, oncology, cardiovascular conditions, and rare genetic disorders. The current investor narrative is intensely focused on the company's transition beyond its pandemic-driven revenue peak, with debates centered on the commercial success of its next-generation respiratory vaccines, the progress and potential of its expansive clinical pipeline, and the resolution of significant legal overhangs, as evidenced by recent news of a major settlement and ongoing patent litigation.…
MRNA
Moderna
$50.73
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating & Thesis: Hold. Moderna is a high-risk, high-potential turnaround story where explosive technical momentum is disconnected from deteriorating fundamentals, requiring investors to await clearer signs of commercial pipeline success before committing new capital. The mixed analyst sentiment, with ratings spanning from 'Overweight' to 'Underperform', reflects this profound uncertainty.
Supporting Evidence: The stock trades at a premium EV/Sales of 8.80x despite a -29% YoY revenue decline in its latest quarter. While the balance sheet is strong (Current Ratio: 3.29), profitability metrics are deeply negative (Net Margin: -121.8%, ROE: -32.6%). The primary bull case is anchored on analyst projections for a revenue recovery to an average of $6.66 billion, but the path to achieving this is unclear given the lumpy quarterly sales and massive ongoing R&D investment of $775 million last quarter alone.
Risks & Conditions: The two biggest risks are the continuation of severe cash burn (-$2.054B TTM FCF) and further commercial disappointments leading to revenue misses. This Hold rating would upgrade to a Buy if the company demonstrates sustained quarterly revenue growth above $1.5 billion with expanding gross margins, or if a major pipeline candidate reports unequivocally positive Phase 3 data. It would downgrade to a Sell if quarterly cash burn accelerates beyond -$600 million or if revenue fails to show sequential growth for two consecutive quarters. Currently, the stock appears fairly valued relative to its own compressed history but overvalued relative to its near-term fundamentals.
Sign up to view all
MRNA 12-Month Price Forecast
Moderna is a binary investment proposition where the current price balances substantial platform potential against near-term operational frailty. The neutral stance reflects the high probability (50%) of a volatile, range-bound base case where the company 'muddles through' without a decisive catalyst. The stance would upgrade to bullish on evidence of commercial traction in new vaccines translating to sustained revenue above $7 billion and expanding margins. It would turn bearish if quarterly cash burn fails to improve or if the stock breaks below key technical support near $45, signaling a failure of the recent momentum.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $65.95 and implied upside of +30.0% versus the current price.
Average Target
$65.95
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$41 - $66
Analyst target range
Analyst coverage is limited, with only 9 analysts providing estimates, indicating this is a stock with high uncertainty and less institutional research scrutiny. The consensus sentiment appears mixed to neutral, as reflected in recent institutional ratings which include actions like 'Overweight', 'Sector Perform', 'Neutral', 'Equal Weight', and 'Underperform', with no clear bullish or bearish consensus emerging from the recent data. The average revenue target for the coming period is $6.66 billion, with a wide range from a low of $5.46 billion to a high of $9.90 billion, implying significant divergence in views on the company's commercial execution. This exceptionally wide target range, spanning over $4.4 billion, signals very high uncertainty among analysts regarding Moderna's near-term revenue trajectory, likely driven by unpredictable vaccine demand, pipeline readout timelines, and competitive dynamics. The pattern of recent ratings shows no major shifts, with most firms reiterating existing positions, suggesting analysts are in a 'wait-and-see' mode pending more concrete clinical or commercial data.
Bulls vs Bears: MRNA Investment Factors
The investment debate for Moderna is a classic battle between powerful technical momentum and a deeply challenged fundamental picture. The bull side currently has stronger short-term evidence, driven by a 117% yearly rally, a resolved legal overhang, and a valuation that has reset from speculative extremes. However, the bear case is grounded in severe operational realities: a -29% YoY revenue decline, a -$826 million quarterly net loss, and a -$2 billion annual cash burn. The single most important tension is the timeline and commercial success of its non-COVID pipeline. If the next-generation respiratory vaccines and other clinical candidates can generate sustainable revenue before cash reserves deplete meaningfully, the bull thesis will be validated. If pipeline readouts disappoint or commercialization stalls, the current high valuation multiples and negative profitability will be untenable, leading to a significant correction.
Bullish
- Powerful Technical Uptrend: The stock has surged 117.36% over the past year and 106.54% over the past six months, demonstrating strong momentum. It is currently trading at $53.72, significantly above its 52-week low of $22.28, indicating a sustained bullish trend.
- Strong Balance Sheet & Liquidity: The company maintains a robust current ratio of 3.29 and a low debt-to-equity ratio of 0.22. This provides significant financial flexibility to fund its expansive R&D pipeline, which cost $775 million in Q4 2025 alone, without immediate solvency concerns.
- Major Legal Overhang Resolved: Recent news highlights a $950 million settlement that cleared a significant legal threat. This removes a key source of uncertainty and allows management to focus on commercial execution and pipeline development, a positive catalyst reflected in recent price action.
- Valuation Compressed from Pandemic Peaks: The current Price-to-Sales ratio of 5.90x is near the lower end of its historical range, having compressed dramatically from figures above 200x. This suggests much of the speculative excess has been wrung out, potentially creating a more reasonable entry point for the platform's long-term potential.
Bearish
- Severe Revenue Decline & Profitability Crisis: Q4 2025 revenue fell 29.08% year-over-year to $678 million, and the company posted a net loss of -$826 million with a net margin of -121.8%. This underscores the challenging transition away from pandemic-era COVID vaccine sales.
- Extremely Volatile & Lumpy Financials: Quarterly revenue in 2025 swung wildly from $107 million in Q1 to $1.016 billion in Q3, highlighting dependence on episodic product sales. Gross margin volatility, from 0.79% in Q3 to 33.33% in Q4, reveals severe operating leverage challenges.
- Massive Cash Burn Funding Pipeline: Trailing twelve-month free cash flow is deeply negative at -$2.054 billion, as the company invests heavily in R&D. With a negative P/CF ratio of -6.12, the business is consuming cash reserves to fund its 35 clinical-stage candidates, creating a long runway to profitability.
- High Uncertainty & Mixed Analyst Sentiment: Only 9 analysts cover the stock, signaling high uncertainty, and their revenue targets range widely from $5.46B to $9.90B. Recent institutional ratings are mixed ('Overweight' to 'Underperform'), reflecting no clear consensus on the near-term trajectory.
MRNA Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +117.36% and a 6-month gain of +106.54%. As of the latest close at $53.72, the price is trading approximately 78% of the way up from its 52-week low of $22.28 towards its high of $59.55, indicating strong momentum but also positioning it closer to a key technical resistance level where further gains may require new catalysts. Recent momentum shows signs of consolidation after a sharp run-up; the stock gained 28.42% over the past three months but only 2.52% over the past month, suggesting the explosive rally may be pausing as the market digests recent moves and awaits new fundamental data. This deceleration is further highlighted by a negative 1-month relative strength of -4.84% versus the SPY, indicating short-term underperformance. Key technical levels are clearly defined by the 52-week high of $59.55 as immediate resistance and the 52-week low of $22.28 as major support. A decisive breakout above $59.55 would signal a resumption of the primary bullish trend, while a breakdown below the recent consolidation range could trigger a deeper pullback. The stock's beta of 1.336 confirms it is approximately 34% more volatile than the broader market, which is typical for a clinical-stage biotech and necessitates larger position-sizing buffers to account for amplified price swings.
Beta
1.34
1.34x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$60
Price range past year
Annual Return
+85.2%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | -5.2% | +8.7% |
| 3m | +4.1% | +3.6% |
| 6m | +89.7% | +5.4% |
| 1y | +85.2% | +30.6% |
| ytd | +64.4% | +4.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Revenue is in a state of significant transition and year-over-year decline, with Q4 2025 revenue of $678 million representing a -29.08% drop from the prior year period, reflecting the post-pandemic normalization of COVID vaccine sales. The quarterly trend through 2025 shows extreme volatility, from a low of $107 million in Q1 to a high of $1.016 billion in Q3, underscoring the lumpy, episodic nature of its current commercial business, which is almost entirely dependent on 'Product Sales' of $1.052 billion as per segment data. The company is currently unprofitable, posting a net loss of -$826 million and a net margin of -121.8% in Q4 2025, though the gross margin of 33.33% for that quarter showed a significant sequential improvement from the near-zero 0.79% gross margin in Q3. This margin volatility highlights the high fixed-cost structure and operating leverage challenges when revenue fluctuates wildly; the operating margin was -126.4% in Q4. The balance sheet remains a key strength, with a robust current ratio of 3.29 and a manageable debt-to-equity ratio of 0.22, indicating strong liquidity and low financial leverage. However, cash flow generation is inconsistent; while Q4 2025 showed positive operating cash flow of $951 million, the trailing twelve-month free cash flow is deeply negative at -$2.054 billion, reflecting the massive ongoing investment in research and development (R&D expense was $775 million in Q4 alone) as the company funds its expansive pipeline, leaving it reliant on its existing cash reserves to fund operations.
Quarterly Revenue
$678000000.0B
2025-12
Revenue YoY Growth
-0.29%
YoY Comparison
Gross Margin
+0.33%
Latest Quarter
Free Cash Flow
$-2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Moderna trades at a trailing PS ratio of 5.90x and an Enterprise Value-to-Sales (EV/Sales) of 8.80x. The forward-looking analyst revenue estimate of $6.66 billion for the coming period suggests the market is pricing in a significant revenue recovery. Compared to typical biotechnology industry averages, which often range in the mid-to-high single digits for EV/Sales, Moderna's 8.80x multiple sits at a premium, reflecting its status as a platform company with a validated technology and a deep pipeline, rather than a single-asset biotech. Historically, Moderna's valuation has compressed dramatically from its pandemic peaks; its current PS ratio of 5.90x is near the lower end of its own historical range, which saw figures above 200x during periods of minimal revenue in early 2024. This suggests the stock is no longer priced for perfection and much of the speculative excess has been wrung out, but it also reflects the market's current skepticism about the near-term commercial trajectory and the timeline for pipeline catalysts to materialize into sustainable revenue.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -13x~495x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Moderna faces acute profitability and cash flow risks. The company is deeply unprofitable, with a Q4 2025 net margin of -121.8% and an operating margin of -126.4%, indicating costs are vastly outstripping revenue. This is exacerbated by extreme revenue volatility, with quarterly sales in 2025 ranging from $107 million to $1.016 billion, creating severe operating leverage challenges. Most critically, the company is burning cash at an alarming rate to fund its pipeline, with TTM free cash flow of -$2.054 billion, threatening its ability to self-fund operations long-term without diluting shareholders or taking on debt.
Market & Competitive Risks: The stock carries significant valuation compression risk, trading at a premium EV/Sales of 8.80x compared to typical biotech industry averages. With a beta of 1.336, it is 34% more volatile than the market, making it highly sensitive to sector rotations away from high-risk, high-growth names. Competitively, the mRNA landscape is intensifying, as evidenced by BioNTech's founders launching a new venture, while ongoing patent litigation (e.g., the BioNTech lawsuit) creates potential for costly settlements or royalties that could erode future margins on key products.
Worst-Case Scenario: The worst-case scenario involves a combination of pipeline failures, continued commercial disappointment in respiratory vaccines, and a sustained market downturn for biotech. This could trigger a rapid de-rating as the market prices in a prolonged period of cash burn without a clear path to profitability. Realistic downside could see the stock re-test its 52-week low of $22.28, representing a -59% decline from the current price of $53.72. A drawdown of this magnitude is plausible given the stock's historical max drawdown of -35.58% and the fundamental fragility of its current financials.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: The company is burning cash at an unsustainable rate (-$2.054B TTM FCF) to fund R&D while being deeply unprofitable (Net Margin: -121.8%). 2) Commercial Execution Risk: Revenue is highly volatile and declining (-29% YoY), with dependence on successful launches of new vaccines. 3) Clinical & Pipeline Risk: The value hinges on 35 clinical-stage candidates; any major trial failure could crater sentiment. 4) Competitive/Legal Risk: Ongoing patent litigation (e.g., with BioNTech) and new mRNA competitors pose threats to market share and margins.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $45 and $60, as revenue stabilizes near analyst averages of $6.66B without major breakthroughs. The Bull Case (25% probability) could drive shares to $65-$75 on successful new vaccine launches and positive clinical data. The Bear Case (25% probability) could see a re-test of support near the 52-week low of $22.28, falling to a range of $22-$35 on commercial disappointments and sustained cash burn. The Base Case is most likely, implying a volatile, range-bound year.
MRNA's valuation is dichotomous. Relative to its own history, it is undervalued, with a Price-to-Sales ratio of 5.90x, down dramatically from pandemic peaks above 200x. However, relative to its current fundamentals—negative earnings, negative cash flow, and declining revenue—its Enterprise Value-to-Sales multiple of 8.80x sits at a premium to the biotech sector. The market is pricing in a significant revenue recovery (analyst avg: $6.66B) and future pipeline success. Therefore, it is fairly valued to slightly overvalued based on near-term metrics, but could be undervalued if its long-term platform potential is realized.
MRNA is a high-risk, high-reward proposition that is not a 'good buy' for most investors. For aggressive investors with a long-term horizon and high risk tolerance, it represents a speculative bet on a leading technology platform. The stock has 117% upside momentum but faces a -29% YoY revenue decline and a -$2 billion annual cash burn. Its attractiveness depends entirely on one's belief in the commercial success of its non-COVID pipeline before cash runs low. Given the profound uncertainty, a 'Hold' and wait-for-clarity approach is more prudent than establishing a new position at current levels.
MRNA is strictly a long-term investment for those willing to wait 3-5 years for its pipeline to mature. The stock's high beta of 1.336 and lack of dividends make it unsuitable for short-term trading or income portfolios. Its value is entirely tied to future clinical and commercial outcomes that will unfold over multiple years. Given the massive cash burn funding this pipeline, investors must be prepared for significant volatility and have an investment horizon that allows the company's strategy to play out. A minimum holding period of 3 years is suggested to weather the inevitable clinical and earnings volatility.